Streetbeat News

SAVA

Cassava Sciences, Inc.

https://www.cassavasciences.com

Industry

Biotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Open

26.46

Mkt cap

1.3B

Volume

2.8M

High

28.99

P/E Ratio

-19.50

52-wk high

42.20

Low

25.46

Div yield

N/A

52-wk low

8.79

Cassava Sciences has appointed Freda Nassif as Chief Commercial Officer. Ms. Nassif has a strong background in developing commercial strategies for FDA-approved drugs, which could enhance Cassava's market presence.

Portfolio Pulse from

November 18, 2024 | 1:45 pm

The article compares the performance of Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) against their sector in the medical stocks category for the current year.

Portfolio Pulse from

November 15, 2024 | 4:00 pm

Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy) due to growing optimism about its earnings prospects, indicating potential upward movement in its stock price.

Portfolio Pulse from

November 12, 2024 | 6:15 pm

The article discusses the effectiveness of Panax ginseng, Anavex's Blarcamesine, and Cassava Sciences' Simufilam in treating Alzheimer's disease. Panax ginseng shows the highest effectiveness, while Anavex's Blarcamesine may slow progression in mild cases. Cassava Sciences' Simufilam shows limited effectiveness.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

Cassava Sciences, Inc. (SAVA) held its Q3 2024 earnings call, discussing financial results and company updates.

Portfolio Pulse from

November 07, 2024 | 3:30 pm

Cassava Sciences, Inc. (Nasdaq: SAVA) has released its financial results for Q3 2024. The company is focused on developing treatments for Alzheimer's disease.

Portfolio Pulse from

November 07, 2024 | 1:15 pm

Cassava Sciences (NYSE:SAVA) has seen a 7.42% increase in its short percent of float, now at 42.12%. This high short interest suggests bearish sentiment, but it could also lead to a short squeeze if the stock price rises. Compared to its peers, Cassava has a significantly higher short interest.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 7:00 pm

The article highlights unusual options activity in the healthcare sector, focusing on trades involving companies like ABT, DXCM, MOH, CAPR, EWTX, SAVA, SMMT, VKTX, GPCR, and HUM. These trades, tracked by Benzinga's options activity scanner, indicate potential trading opportunities based on the sentiment and volume of options traded.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 5:35 pm

Cassava Sciences (NASDAQ:SAVA) has significantly outperformed the market over the past 5 years, with an annualized return of 67.63% and an average annual return of 81.65%. A $1000 investment in SAVA 5 years ago would now be worth $19,936.51.

Portfolio Pulse from Benzinga Insights

October 09, 2024 | 7:30 pm

U.S. stocks rose with the Nasdaq gaining 200 points. The U.S. trade deficit narrowed to $70.4 billion in August. Alternus Clean Energy, Bio-Path Holdings, and Cassava Sciences saw significant stock price increases, while ZJK Industrial, JinkoSolar, and Lufax Holding experienced declines. Crude oil prices fell over 4%.

Portfolio Pulse from Avi Kapoor

October 08, 2024 | 4:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.